Repligen Corporation $RGEN Shares Sold by Rhumbline Advisers

Rhumbline Advisers trimmed its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 2.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 142,113 shares of the biotechnology company’s stock after selling 4,018 shares during the period. Rhumbline Advisers’ holdings in Repligen were worth $17,676,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Price T Rowe Associates Inc. MD raised its holdings in shares of Repligen by 6.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock worth $962,711,000 after purchasing an additional 430,039 shares during the last quarter. Alliancebernstein L.P. grew its position in Repligen by 1.3% during the 1st quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company’s stock worth $130,317,000 after purchasing an additional 13,284 shares during the period. Northern Trust Corp grew its position in Repligen by 1.0% during the 1st quarter. Northern Trust Corp now owns 498,447 shares of the biotechnology company’s stock worth $63,422,000 after purchasing an additional 4,734 shares during the period. Geneva Capital Management LLC raised its stake in shares of Repligen by 239.6% during the 2nd quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock valued at $60,639,000 after buying an additional 343,991 shares during the last quarter. Finally, Alyeska Investment Group L.P. lifted its holdings in shares of Repligen by 24.0% in the 1st quarter. Alyeska Investment Group L.P. now owns 460,237 shares of the biotechnology company’s stock valued at $58,561,000 after buying an additional 89,057 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Performance

RGEN opened at $171.11 on Friday. The firm’s fifty day simple moving average is $149.72 and its two-hundred day simple moving average is $131.77. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $182.52. The company has a market cap of $9.63 billion, a price-to-earnings ratio of 8,559.78, a PEG ratio of 3.32 and a beta of 1.15. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The firm had revenue of $188.81 million during the quarter, compared to the consensus estimate of $181.23 million. During the same quarter in the prior year, the firm earned $0.43 EPS. The company’s revenue for the quarter was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Equities analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $205.00 target price on shares of Repligen in a report on Tuesday, September 2nd. Jefferies Financial Group set a $160.00 price target on shares of Repligen and gave the stock a “hold” rating in a report on Tuesday, October 28th. HSBC began coverage on shares of Repligen in a report on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price objective for the company. Finally, Hsbc Global Res raised shares of Repligen to a “strong-buy” rating in a research note on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and an average target price of $173.85.

Insider Activity at Repligen

In other Repligen news, COO James Bylund sold 2,191 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the transaction, the chief operating officer owned 21,520 shares in the company, valued at approximately $3,254,039.20. This trade represents a 9.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Anthony Hunt sold 25,000 shares of Repligen stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $156.88, for a total transaction of $3,922,000.00. Following the sale, the director directly owned 100,743 shares in the company, valued at approximately $15,804,561.84. This trade represents a 19.88% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 49,382 shares of company stock worth $7,676,802. Company insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.